EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Speech‐based digital cognitive assessment for clinical trials: Detecting cognitive impairment stages and AD biomarker relations across European cohorts

Alexandra König iD, Johannes Tröger, Elisa Mallick, Nicklas Linz iD, Craig Ritchie iD, Sarah Gregory iD, Matthew Hunter iD, Kay Johnson, Gonzalo Sánchez Benavides iD, Oriol Grau-Rivera iD, Andreea Radoi iD, Claudia Porta-Mas iD und 6 weitere

Alzheimer's & Dementia · 2026-05 · 22 (5)

DOI: 10.1002/alz.71462 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 18.05.2026. Verfasst von Alexandra König und 17 weiteren Autor:innen. Beteiligte Einrichtung: ki:elements GmbH, Saarbrücken, Germany. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction, Speech. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Alzheimer Foundation, Rönström Family Foundation, Skåne University Hospital Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Early detection of Alzheimer's disease (AD) is critical for timely intervention as disease‐modifying treatments emerge. Speech‐based digital biomarkers offer scalable options for remotely capturing speech‐derived functional changes associated with early cognitive decline, but validation across real‐world populations remains limited. METHODS We evaluated the speech biomarker for cognition (SB‐C), an automated speech‐derived measure associated with cognitive status, in 736 participants across five European cohorts (Barcelonaβeta Brain Research Center's Alzheimer's at‐risk cohort, European Prevention of Alzheimer's Dementia Scotland, Dementia Study of Cognitive and Biomarker Dynamics, Longitudinal Cognitive Impairment and Dementia Study, and Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably [BioFINDER‐Primary Care]). Participants completed verbal learning and semantic fluency tasks via automated phone or app‐based platforms. SB‐C performance was compared to Mini‐Mental State Examination, Clinical Dementia Rating, Preclinical Alzheimer Cognitive Composite 5, and cerebrospinal fluid amyloid beta and phosphorylated tau181 biomarker status. RESULTS SB‐C significantly differentiated cognitively unimpaired and impaired groups ( P < 0.001), correlated with standard cognitive measures, and showed moderate‐to‐high area under the curve (0.56–0.82) for classifying biomarker positivity, with strongest results in BioFINDER‐Primary Care. DISCUSSION SB‐C is a scalable, remote speech‐derived marker associated with cognitive status and AD biomarker group differences.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseCognitive DysfunctionSpeechHumansMaleFemaleBiomarkersEuropeAgedAmyloid beta-Peptidestau ProteinsNeuropsychological TestsCohort StudiesEarly DiagnosisAged, 80 and overClinical Trials as Topic

Stichwörter der Autor:innen

Alzheimer's diseasecerebrospinal fluid biomarkersmild cognitive impairmentremote cognitive assessmentspeech‐based digital biomarkerssubjective cognitive decline

Substanzen

BiomarkersAmyloid beta-Peptidestau Proteins

Autor:innen und Institutionen

  • ki:elements GmbH, Saarbrücken, Germany.
  • Cobtek (Cognition-Behaviour-Technology) Lab, FRIS-University Côte d'azur, Nice, France.
  • Centre Hospitalier et Universitaire, Clinique Gériatrique du Cerveau et du Mouvement, Centre Mémoire de Ressources et de Recherche, Université Côte d'Azur, Nice, France.
  • Scottish Brain Science, Edinburgh, UK.
  • Brain Health and Neurodegenerative Medicine, University of St. Andrews, St. Andrews, UK.
  • Edinburgh Dementia Prevention, University of Edinburgh, Edinburgh, UK.

ORCID-Profile: Alexandra König, Nicklas Linz, Craig Ritchie, Sarah Gregory, Matthew Hunter, Gonzalo Sánchez Benavides, Oriol Grau-Rivera, Andreea Radoi, Claudia Porta-Mas, Stefanie Köhler, Stefan Teipel, Oskar Hansson, Pontus Tideman, Anika Wuestefeld, Sebastian Palmqvist

Förderung

  • Swedish Alzheimer Foundation
  • Rönström Family Foundation
  • Skåne University Hospital Foundation
  • Kamprad Foundation
  • Regionalt Forskningsstöd
  • Alzheimer's Drug Discovery Foundation (ADDF)
  • ERA PerMed
  • Swedish federal government

Zitieren

APA

König, A., Tröger, J., Mallick, E., Linz, N., Ritchie, C., Gregory, S., Hunter, M., Johnson, K., Benavides, G. S., Grau-Rivera, O., Radoi, A., Porta-Mas, C., Köhler, S., Teipel, S., Hansson, O., Tideman, P., Wuestefeld, A., & Palmqvist, S. (2026). Speech‐based digital cognitive assessment for clinical trials: Detecting cognitive impairment stages and AD biomarker relations across European cohorts. Alzheimer's & Dementia, 22(5). https://doi.org/10.1002/alz.71462

Vancouver

König A, Tröger J, Mallick E, Linz N, Ritchie C, Gregory S, et al. Speech‐based digital cognitive assessment for clinical trials: Detecting cognitive impairment stages and AD biomarker relations across European cohorts. Alzheimer's & Dementia. 2026;22(5). doi:10.1002/alz.71462

BibTeX
@article{Knig2026,
  author = {König, Alexandra and Tröger, Johannes and Mallick, Elisa and Linz, Nicklas and Ritchie, Craig and Gregory, Sarah and Hunter, Matthew and Johnson, Kay and Benavides, Gonzalo Sánchez and Grau-Rivera, Oriol and Radoi, Andreea and Porta-Mas, Claudia and Köhler, Stefanie and Teipel, Stefan and Hansson, Oskar and Tideman, Pontus and Wuestefeld, Anika and Palmqvist, Sebastian},
  title = {Speech‐based digital cognitive assessment for clinical trials: Detecting cognitive impairment stages and AD biomarker relations across European cohorts},
  journal = {Alzheimer's & Dementia},
  year = {2026},
  volume = {22},
  number = {5},
  doi = {10.1002/alz.71462}
}
Kostenlos starten →